AKROSWISS
Akroswiss is a Swiss pharmaceutical company that is developing new intranasal formulations in CNS.
AKROSWISS
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2007-06-07
Address:
Zug, Zug, Switzerland
Country:
Switzerland
Website Url:
http://www.akroswiss.ch
Total Employee:
1+
Status:
Active
Total Funding:
3 M CHF
Technology used in webpage:
Organization Schema Person Schema U.S. Server Location
Similar Organizations
Alvion Pharmaceuticals P.C.
Pharmaceutical company
Amyndas Pharmaceuticals S.A.
Amyndas is a pharmaceutical company
Dayton Therapeutics
Pharmaceuticals, Biotech, Oncology
Jenrin Discovery
Jenrin Discovery is a biopharmaceutical Company.
Mits lifesciences
Pharmaceuticals company
Novo Nordisk Pharmatech
Pharmaceutical company
Palmira Biopharma
Biopharmaceutical company
Current Employees Featured
Founder
Official Site Inspections
http://www.akroswiss.ch Semrush global rank: 7.35 M Semrush visits lastest month: 805
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Akroswiss"
Akroswiss takes a step forward in the interest of patients closing a ...
May 17, 2021 Akroswiss has successfully developed and tested a unique Bi-dose nasal drug delivery device for Midazolam with a first-class 360° functionality. The development of these …See details»
Akroswiss - Crunchbase Company Profile & Funding
Akroswiss closed its last funding round on May 17, 2021 from a Seed round. Who are Akroswiss 's competitors? Alternatives and possible competitors to Akroswiss may include Jenrin …See details»
AKROSWISS AG Company Profile | Zug, ZUG, Switzerland
Find company research, competitor information, contact details & financial data for AKROSWISS AG of Zug, ZUG. Get the latest business insights from Dun & Bradstreet.See details»
Akroswiss Company Profile 2024: Valuation, Funding & Investors
Www.akroswiss.ch. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. Baarerstrasse 2; 6300 Zug; Switzerland ... Bernhard Schuknecht, …See details»
Akroswiss AG - startup.ch
Akroswiss AG: Akroswiss aims to develop, manufacture, and commercialize innovative nasal treatments in CNS. We are pursuing EMA marketing authorization for our two indications in Anxiolytics and Epileptics. ...See details»
Akroswiss - LinkedIn
Akroswiss is a swiss based pharmaceutical company, fully dedicated to the development and commercialization of innovative nasal applications of midazolam.See details»
Akroswiss - Products, Competitors, Financials, Employees, …
May 18, 2021 Akroswiss is a pharmaceutical company focused on the development of innovative nasal treatments in the central nervous system (CNS) domain. The company specializes in …See details»
Akroswiss takes a step forward in the interest of patients closing a ...
Akroswiss AG www.akroswiss.ch Marc Fröhlich Mail: [email protected] Phone: +41 (0)79 766 88 42 ... CyberArk SaaS products are now available in the ACN marketplace to any …See details»
Akroswiss takes a step forward in the interest of patients closing a ...
Akroswiss is developing an innovative and patented Midazolam-based nasal spray to treat patients suffering from claustrophobia and epileptic seizures. In April, the Swiss start-up has …See details»
Akroswiss - Overview, News & Similar companies | ZoomInfo.com
Akroswiss Closes Multi-Million CHF Seed Funding Round Akroswiss, a Zug, Switzerland-based developer of an innovative and patented Midazolam-based nasal spray to treat patients …See details»
Akroswiss : takes a step forward in the interest of patients closing …
May 17, 2021 Akroswiss is developing an innovative and patented Midazolam-based nasal spray to treat patients suffering from claustrophobia and epileptic seizures. In April, the Swiss start …See details»
Akroswiss takes a step forward in the interest of patients closing a ...
May 17, 2021 ZUG, Switzerland– Akroswiss is developing an innovative and patented Midazolam-based nasal spray to treat patients suffering from claustrophobia and epileptic …See details»
Akroswiss - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . May 17, 2021: Seed Round - …See details»
Akroswiss Closes Multi-Million CHF Seed Funding Round - FinSMEs
May 18, 2021 Akroswiss, a Zug, Switzerland-based developer of an innovative and patented Midazolam-based nasal spray to treat patients suffering from claustrophobia and epileptic …See details»
AKROSWISS | Business Wire - Ritzau
Akroswiss has successfully developed and tested a unique Bi-dose nasal drug delivery device for Midazolam with a first-class 360° functionality. The development of these Midazolam …See details»
Marc Fröhlich – Zürich, Schweiz | Berufliches Profil | LinkedIn
CEO at Akroswiss | Board Member at Klus-Apotheke · Berufserfahrung: Everyman Health · Ausbildung: Stockholm School of Economics · Standort: Zürich · 500+ Kontakte auf LinkedIn. …See details»
Start-up develops nasal spray against fear - ZUG4YOU
The so-called seed financing was provided by Akroswiss AG, based in Zug, which also manages the licensing rights. Akroswiss employs only a handful of people, but relies on many external …See details»
Jonas Steinhauser - Research & Development Director - Akroswiss …
Resourceful and versatile R&D leader with a unique combination of skills develops innovative products for Akroswiss. · As a project leader at Akroswiss, I bring my experience and expertise …See details»
News - Akroswiss
Akroswiss takes a step forward in the interest of patients closing a multi-million CHF funding round. ZUG, Switzerland: May 17, 2021 Akroswiss is developing an innovative and patented …See details»
Akroswiss kommt im Interesse der Patienten einen Schritt voran …
May 17, 2021 Akroswiss kommt im Interesse der Patienten einen Schritt voran und schließt eine Seed-Series-Finanzierungsrunde in Höhe mehrerer Millionen Schweizer Franken ab May 17, …See details»